FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2416192894> ?p ?o ?g. }

• W2416192894 endingPage "666.e1" @default.
• W2416192894 startingPage "657" @default.
• W2416192894 abstract "ObjectiveBecause models of attention-deficit/hyperactivity disorder (ADHD) therapeutics emphasize benefits of both enhanced dopaminergic and noradrenergic signaling, strategies to enhance D1 and α2A agonism may yield enhanced clinical and cognitive responses. This study tested the hypothesis that combined effects of a dopamine and noradrenergic agonist, d-methylphenidate extended-release (DMPH) with guanfacine (GUAN), an α2A receptor agonist, would be clinically superior to either monotherapy and would have equal tolerability.MethodAn 8-week, double-blind, 3-arm, comparative trial randomized 7- to 14-year-olds with DSM-IV ADHD to GUAN (1−3 mg/day), DMPH (5−20 mg/day), or a combination (COMB) with fixed-flexible dosing. Outcome measures were the ADHD Rating Scale IV (ADHD-RS-IV) and the Clinical Global Impression−Improvement (CGI-I) scale. Data on adverse events and safety measures were obtained.ResultsA total of 207 participants were randomized and received drug. Analyses showed significant treatment group main effects for ADHD-RS-IV ADHD total (p = .0001) and inattentive symptoms (p = .0001). COMB demonstrated small but consistently greater reductions in ADHD-RS-IV Inattentive subscale scores versus monotherapies (DMPH: p = .05; f2 = .02; and GUAN: p = .02; f2 = .02), and was associated with a greater positive response rate by CGI-I (p = .01). No serious cardiovascular events occurred. Sedation, somnolence, lethargy, and fatigue were greater in both guanfacine groups. All treatments were well tolerated.ConclusionCOMB showed consistent evidence of clinical benefits over monotherapies, possibly reflecting advantages of greater combined dopaminergic and α2A agonism. Adverse events were generally mild to moderate, and COMB treatment showed no differences in safety or tolerability.Clinical trial registration information: Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder (Project1); http://clinicaltrials.gov/; NCT00429273. Because models of attention-deficit/hyperactivity disorder (ADHD) therapeutics emphasize benefits of both enhanced dopaminergic and noradrenergic signaling, strategies to enhance D1 and α2A agonism may yield enhanced clinical and cognitive responses. This study tested the hypothesis that combined effects of a dopamine and noradrenergic agonist, d-methylphenidate extended-release (DMPH) with guanfacine (GUAN), an α2A receptor agonist, would be clinically superior to either monotherapy and would have equal tolerability. An 8-week, double-blind, 3-arm, comparative trial randomized 7- to 14-year-olds with DSM-IV ADHD to GUAN (1−3 mg/day), DMPH (5−20 mg/day), or a combination (COMB) with fixed-flexible dosing. Outcome measures were the ADHD Rating Scale IV (ADHD-RS-IV) and the Clinical Global Impression−Improvement (CGI-I) scale. Data on adverse events and safety measures were obtained. A total of 207 participants were randomized and received drug. Analyses showed significant treatment group main effects for ADHD-RS-IV ADHD total (p = .0001) and inattentive symptoms (p = .0001). COMB demonstrated small but consistently greater reductions in ADHD-RS-IV Inattentive subscale scores versus monotherapies (DMPH: p = .05; f2 = .02; and GUAN: p = .02; f2 = .02), and was associated with a greater positive response rate by CGI-I (p = .01). No serious cardiovascular events occurred. Sedation, somnolence, lethargy, and fatigue were greater in both guanfacine groups. All treatments were well tolerated. COMB showed consistent evidence of clinical benefits over monotherapies, possibly reflecting advantages of greater combined dopaminergic and α2A agonism. Adverse events were generally mild to moderate, and COMB treatment showed no differences in safety or tolerability." @default.
• W2416192894 created "2016-06-24" @default.
• W2416192894 creator A5010368679 @default.
• W2416192894 creator A5015216843 @default.
• W2416192894 creator A5027244148 @default.
• W2416192894 creator A5028818113 @default.
• W2416192894 creator A5041676273 @default.
• W2416192894 creator A5041808631 @default.
• W2416192894 creator A5044457835 @default.
• W2416192894 creator A5046157340 @default.
• W2416192894 creator A5052303749 @default.
• W2416192894 creator A5061813899 @default.
• W2416192894 creator A5064876957 @default.
• W2416192894 date "2016-08-01" @default.
• W2416192894 modified "2023-10-11" @default.
• W2416192894 title "Combined Stimulant and Guanfacine Administration in Attention-Deficit/Hyperactivity Disorder: A Controlled, Comparative Study" @default.
• W2416192894 cites W1519906268 @default.
• W2416192894 cites W1849348377 @default.
• W2416192894 cites W1963573639 @default.
• W2416192894 cites W1964309132 @default.
• W2416192894 cites W1970966565 @default.
• W2416192894 cites W1972639908 @default.
• W2416192894 cites W1976881402 @default.
• W2416192894 cites W1980324473 @default.
• W2416192894 cites W1984621943 @default.
• W2416192894 cites W1988882510 @default.
• W2416192894 cites W1992749619 @default.
• W2416192894 cites W1999058928 @default.
• W2416192894 cites W2002134787 @default.
• W2416192894 cites W2014951345 @default.
• W2416192894 cites W2017449681 @default.
• W2416192894 cites W2022741651 @default.
• W2416192894 cites W2025218992 @default.
• W2416192894 cites W2030480409 @default.
• W2416192894 cites W2031947904 @default.
• W2416192894 cites W2032268094 @default.
• W2416192894 cites W2032658084 @default.
• W2416192894 cites W2037112455 @default.
• W2416192894 cites W2039528900 @default.
• W2416192894 cites W2039607158 @default.
• W2416192894 cites W2039762616 @default.
• W2416192894 cites W2046835548 @default.
• W2416192894 cites W2059171296 @default.
• W2416192894 cites W2061615124 @default.
• W2416192894 cites W2067292897 @default.
• W2416192894 cites W2071199156 @default.
• W2416192894 cites W2074521517 @default.
• W2416192894 cites W2079165280 @default.
• W2416192894 cites W2082765847 @default.
• W2416192894 cites W2086177964 @default.
• W2416192894 cites W2086746663 @default.
• W2416192894 cites W2091029144 @default.
• W2416192894 cites W2110145837 @default.
• W2416192894 cites W2112374643 @default.
• W2416192894 cites W2112735398 @default.
• W2416192894 cites W2113372649 @default.
• W2416192894 cites W2114186661 @default.
• W2416192894 cites W2115518880 @default.
• W2416192894 cites W2115728178 @default.
• W2416192894 cites W2115918088 @default.
• W2416192894 cites W2124264649 @default.
• W2416192894 cites W2127760169 @default.
• W2416192894 cites W2128525767 @default.
• W2416192894 cites W2130816992 @default.
• W2416192894 cites W2134421313 @default.
• W2416192894 cites W2138511981 @default.
• W2416192894 cites W2144579914 @default.
• W2416192894 cites W2146601572 @default.
• W2416192894 cites W2146964018 @default.
• W2416192894 cites W2153007969 @default.
• W2416192894 cites W2159337254 @default.
• W2416192894 cites W2266471137 @default.
• W2416192894 cites W2407531858 @default.
• W2416192894 cites W2418067944 @default.
• W2416192894 cites W2601578636 @default.
• W2416192894 doi "https://doi.org/10.1016/j.jaac.2016.05.015" @default.
• W2416192894 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4976782" @default.
• W2416192894 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27453079" @default.
• W2416192894 hasPublicationYear "2016" @default.
• W2416192894 type Work @default.
• W2416192894 sameAs 2416192894 @default.
• W2416192894 citedByCount "34" @default.
• W2416192894 countsByYear W24161928942016 @default.
• W2416192894 countsByYear W24161928942017 @default.
• W2416192894 countsByYear W24161928942018 @default.
• W2416192894 countsByYear W24161928942019 @default.
• W2416192894 countsByYear W24161928942020 @default.
• W2416192894 countsByYear W24161928942021 @default.
• W2416192894 countsByYear W24161928942022 @default.
• W2416192894 countsByYear W24161928942023 @default.
• W2416192894 crossrefType "journal-article" @default.
• W2416192894 hasAuthorship W2416192894A5010368679 @default.
• W2416192894 hasAuthorship W2416192894A5015216843 @default.
• W2416192894 hasAuthorship W2416192894A5027244148 @default.
• W2416192894 hasAuthorship W2416192894A5028818113 @default.
• W2416192894 hasAuthorship W2416192894A5041676273 @default.
• W2416192894 hasAuthorship W2416192894A5041808631 @default.
• W2416192894 hasAuthorship W2416192894A5044457835 @default.

• next